ImmunoPrecise Antibodies Ltd [NASDAQ: IPA] slipped around -0.1 points on Monday, while shares priced at $0.58 at the close of the session, down -15.09%.
Compared to the average trading volume of 219.09K shares, IPA reached a trading volume of 12867218 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
What do top market gurus say about ImmunoPrecise Antibodies Ltd [IPA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IPA shares is $6.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IPA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for ImmunoPrecise Antibodies Ltd shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 02, 2022. While these analysts kept the previous recommendation, The Benchmark Company raised their target price to Buy. The new note on the price target was released on October 25, 2021, representing the official price target for ImmunoPrecise Antibodies Ltd stock.
The Average True Range (ATR) for ImmunoPrecise Antibodies Ltd is set at 0.07, with the Price to Sales ratio for IPA stock in the period of the last 12 months amounting to 0.81. The Price to Book ratio for the last quarter was 0.66, with the Price to Cash per share for the same quarter was set at 0.11.
How has IPA stock performed recently?
ImmunoPrecise Antibodies Ltd [IPA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.59. With this latest performance, IPA shares dropped by -11.07% in over the last four-week period, additionally sinking by -57.97% over the last 6 months – not to mention a drop of -64.89% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IPA stock in for the last two-week period is set at 47.16, with the RSI for the last a single of trading hit 48.83, and the three-weeks RSI is set at 45.78 for ImmunoPrecise Antibodies Ltd [IPA]. The present Moving Average for the last 50 days of trading for this stock 0.6553, while it was recorded at 0.5743 for the last single week of trading, and 1.1476 for the last 200 days.
ImmunoPrecise Antibodies Ltd [IPA]: Deeper insight into the fundamentals
ImmunoPrecise Antibodies Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.82 and a Current Ratio set at 0.99.
Insider trade positions for ImmunoPrecise Antibodies Ltd [IPA]
There are presently around $6.07%, or 6.96%% of IPA stock, in the hands of institutional investors. The top three institutional holders of IPA stocks are: INGALLS & SNYDER LLC with ownership of 1.3 million shares, which is approximately 5.0209%. RENAISSANCE TECHNOLOGIES LLC, holding 63910.0 shares of the stock with an approximate value of $$64549.0 in IPA stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $$61443.0 in IPA stock with ownership which is approximately 0.2165%.
